TheraRadar
← Back
Data updated: Jun 28, 2026

DEPROCO

Generics
Pharmaceuticals

DEPROCO is a generic drug manufacturer with 6 FDA-approved products.

1984
Since
6
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
2 Small Molecules

DEPROCO's Key Drugs

DEPROCO's core commercial portfolio centers on FLAVALTA — its most strategically important drugs approved in the last 15 years.

FLAVALTA
Approved 2026

DEPROCO's Recent FDA Approvals

DEPROCO secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

FLAVALTA NDA
2026-03-19
epinephrine bitartrate
1 INDICATIONS AND USAGE FLAVALTA solution is indicated for the production of local anesthesia for dental procedures by nerve block or infiltration techniques [see Dosage and Administration (2.2) ]. FLAVALTA solution is a combination of lidocaine, an amide local anesthetic, and epinephrine, an alpha and beta adrenergic agonist indicated for the production of local anesthesia for dental procedures by nerve block or infiltration techniques.

DEPROCO's Therapeutic Areas

Disease areas where DEPROCO has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

DEPROCO Pipeline Snapshot

Active clinical trials for DEPROCO across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • FLAVALTA leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling